Clinical Trial Update: Study of Multiple Doses of Saxagliptin (BMS-477118) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating multiple doses of saxagliptin (BMS-477118) in patients with Type 2 Diabetes Mellitus has completed, and the results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Saxagliptin (saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2010-02-23